Paper Details

  1. Home
  2. Paper Details

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Author: , AweekaFrancesca, BaughBryan P, BrownTodd T, CohnSusan E, CurrierJudith S, GodfreyCatherine, KuritzkesDaniel R, LandovitzRaphael J, LeavittRandi Y, LennoxJeffrey L, McComseyGrace A, NaLumine H, OfotokunIghovwerha, ParaMichael F, PattersonKristine B, RibaudoHeather J, SagarManish, Villasis-KeeverAngelina

Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Raltegravir-based combination antiretroviral therapy (cART) produced the most favorable lipid profile compared to ritonavir-boosted atazanavir or darunavir. The metabolic syndrome rates were high at baseline and increased to the same degree in all arms.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type. Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257 study, and correlated with plasma ritonavir trough concentrations (C24). METHODS: Treatmen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660025/

データ提供：米国国立医学図書館（NLM）

The Metabolic Landscape of Antiretroviral Therapy: A Comparison of Regimens

This research explores the metabolic effects of different antiretroviral therapy (cART) regimens in treatment-naive HIV-infected individuals. The study, like a camel traversing the vast desert of HIV research, compares the metabolic profiles of individuals receiving ritonavir-boosted atazanavir or darunavir, and those receiving raltegravir-based cART. The findings reveal that ritonavir-boosted protease inhibitors (PIs) lead to greater increases in lipids compared to raltegravir, highlighting the importance of considering metabolic outcomes when selecting cART regimens.

Navigating the Complexities of Antiretroviral Therapy

This research underscores the importance of understanding the metabolic effects of different cART regimens. The study's findings emphasize the need for careful consideration of metabolic outcomes, particularly lipid levels, when selecting the most appropriate cART regimen for individual patients. This discovery is like finding a hidden map in the desert of HIV treatment, guiding healthcare professionals towards more personalized and effective care for their patients.

Finding the Right Path for Long-Term HIV Management

This research provides valuable insights into the metabolic effects of various cART regimens. The findings highlight the importance of monitoring lipid profiles and considering alternative regimens to minimize potential metabolic complications. This knowledge is crucial for providing long-term care for individuals living with HIV.

Dr.Camel's Conclusion

This study sheds light on the metabolic landscape of antiretroviral therapy, highlighting the importance of tailoring treatment regimens to individual patient needs. The findings emphasize the need for careful monitoring of lipid profiles and considering alternative regimens to minimize potential metabolic complications. This discovery is like finding a hidden oasis in the desert of HIV treatment, offering a potential source of relief for those struggling with this complex condition.

Date :
  1. Date Completed 2016-02-22
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

25767256

DOI: Digital Object Identifier

PMC4660025

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.